Market Cap 167.93M
Revenue (ttm) 146.07M
Net Income (ttm) -196.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -134.21%
Debt to Equity Ratio -0.45
Volume 527,400
Avg Vol 547,452
Day's Range N/A - N/A
Shares Out 22.66M
Stochastic %K 18%
Beta 0.80
Analysts Strong Sell
Price Target $15.57

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
laaarsas
laaarsas Jul. 27 at 11:53 AM
$KPTI when donkeh come home to roost???
0 · Reply
valueinvestor1998
valueinvestor1998 Jul. 27 at 3:07 AM
2 · Reply
celebratelife
celebratelife Jul. 26 at 7:32 PM
$KPTI Hit piece published with plenty of fishy, inaccurate shit, by doctor with conflict of interest. Think Mike Mano, Richard Paulson, Useless, Weak, in their roles, and careless. They've failed to defend the company in the past against unfounded attacks by hedge shills and others. They don't seem to give a shit as long as they get their fucking millions. We may have to do something since they probably won't, and they're too incompetent and careless to know, when you turn the other cheek to bashers they next take a punch to the belly. No wonder shorts LOVE these guys.
2 · Reply
laaarsas
laaarsas Jul. 26 at 1:33 PM
$KPTI donkeeeeeeh
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 25 at 2:20 PM
$TNXP seth is too washed to be CMO. He should be Executive Chairman of the Board with some fancy emeritus title. Tonix needs a real CEO. I have various ways to turn biopharma companies around. I have done so as an employee, a consultant, and a disgruntled- yet vocal- shareholder. CEOs earn their pay or get the 💩 🗑️ in my book $KPTI CEO Richard “tricky dick” Paulson should have been fired YEARS AGO. $IMRX & $SLS … no complaints there. Both companies have competent leadership. 👍 👍 💎 💎 💎 💎 I don’t keep scraps in my scrapbook - only studs. Seth has Got to Go 🥾 Here is one suggestion:
0 · Reply
laaarsas
laaarsas Jul. 24 at 4:51 AM
$KPTI any donkey in da house?
0 · Reply
celebratelife
celebratelife Jul. 23 at 2:12 PM
$KPTI - RBC Capital Markets, which rates the stock at outperform and a $16 price target (~128% upside based on Monday's close) said the sell-off is unwarranted based on conversations it had with the company. Analyst Brian Abrahams said the cash retention program replaces a guaranteed annual bonus. He added it is unlikely the program is related to an upcoming phase 3 data release of Xpovio (selinexor) in endometrial cancer, adding he gives that trial a 65% possibility of success. As much as I dislike this lousy CEO & Board I could not get myself to sell based on the latest compensation news. It wasn't in itself grounds to sell, although emotionally charged since instead of receiving more money Richard Paulson should get fired.
0 · Reply
elmono
elmono Jul. 22 at 8:59 PM
$KPTI 2 wks to deliver data….
1 · Reply
celebratelife
celebratelife Jul. 22 at 8:37 PM
$KPTI I'm sure many long-term investors remember those days, those painful PRs and calls where this lousy horrible CEO who's never given a damn about shareholders except to spend our money, announced time and again, fucking bad news, fucking delays after fucking delays, and his fucking bonus and big pay was never impacted as shareholder value tanked, nose-dived on his fucking watch. He's not the only one to blame. That wicked Board behind him are also adored by shorts who have made a killing as shareholders have lost their shorts. Shareholders trusted this incompetent wicked CEO / Board clowns in heir public facing role as officers of a publicly traded company. Shorts bet against them. Is there corruptioni? Time will tell. We know who's made money anad who's lost money.
2 · Reply
celebratelife
celebratelife Jul. 22 at 3:36 PM
$KPTI KPTI shorts love Richard Party Paulson and the KPTI Board who've been a dream come true for the scumbags who shorted KPTI for the last 6 years since Paulson was a director and then a CEO. Dream Come True for shorts and HELL for decent people who put their hard-earned dollars into this company trusting this lousy CEO and lousy Board.
1 · Reply
Latest News on KPTI
Karyopharm Therapeutics Transcript: Study result

Jun 2, 2026, 2:00 PM EDT - 7 weeks ago

Karyopharm Therapeutics Transcript: Study result


Karyopharm Therapeutics Press release: Study result

Jun 2, 2026, 2:00 PM EDT - 7 weeks ago

Karyopharm Therapeutics Press release: Study result


Karyopharm Therapeutics Slides: Study result

Jun 2, 2026, 2:00 PM EDT - 7 weeks ago

Karyopharm Therapeutics Slides: Study result


Karyopharm Therapeutics Transcript: AGM 2026

May 21, 2026, 9:00 AM EDT - 2 months ago

Karyopharm Therapeutics Transcript: AGM 2026


Karyopharm Therapeutics Slides: Corporate presentation

May 17, 2026, 7:00 AM EDT - 2 months ago

Karyopharm Therapeutics Slides: Corporate presentation


Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)

2026-05-14T12:06:55.000Z - 2 months ago

Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)


Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M

2026-05-14T12:04:59.000Z - 2 months ago

Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M


Karyopharm Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2026


Karyopharm Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Earnings release: Q1 2026


Karyopharm Therapeutics Slides: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Slides: Q1 2026


Karyopharm Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Quarterly report: Q1 2026


Karyopharm to Participate at Upcoming Investor Conferences

May 12, 2026, 7:30 AM EDT - 2 months ago

Karyopharm to Participate at Upcoming Investor Conferences


Karyopharm files $400M mixed securities shelf

2026-05-04T20:43:12.000Z - 3 months ago

Karyopharm files $400M mixed securities shelf


Karyopharm price target raised to $16 from $8 at Piper Sandler

2026-04-27T10:52:35.000Z - 3 months ago

Karyopharm price target raised to $16 from $8 at Piper Sandler


Karyopharm Therapeutics Slides: Corporate presentation

Apr 16, 2026, 7:00 AM EDT - 3 months ago

Karyopharm Therapeutics Slides: Corporate presentation


Karyopharm Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Karyopharm Therapeutics Proxy statement: Proxy filing


Karyopharm price target lowered to $16 from $23 at RBC Capital

2026-04-07T15:11:06.000Z - 3 months ago

Karyopharm price target lowered to $16 from $23 at RBC Capital


Karyopharm price target lowered to $8 from $12 at Piper Sandler

2026-03-30T11:31:21.000Z - 4 months ago

Karyopharm price target lowered to $8 from $12 at Piper Sandler


Karyopharm price target lowered to $15 from $21 at Baird

2026-03-25T11:26:32.000Z - 4 months ago

Karyopharm price target lowered to $15 from $21 at Baird


Karyopharm Therapeutics Transcript: Study result

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Karyopharm Therapeutics Transcript: Study result


Karyopharm Therapeutics Press release: Study result

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Karyopharm Therapeutics Press release: Study result


Karyopharm Therapeutics Slides: Study result

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Karyopharm Therapeutics Slides: Study result


Karyopharm announces $30M private placement

2026-03-24T11:05:33.000Z - 4 months ago

Karyopharm announces $30M private placement


Karyopharm initiated with a Buy at Rodman & Renshaw

2026-03-09T20:20:12.000Z - 5 months ago

Karyopharm initiated with a Buy at Rodman & Renshaw


Karyopharm Therapeutics Transcript: EGM 2026

Feb 18, 2026, 9:00 AM EST - 5 months ago

Karyopharm Therapeutics Transcript: EGM 2026


Karyopharm Therapeutics Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2025


Karyopharm Therapeutics Annual report: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Annual report: Q4 2025


Karyopharm Therapeutics Earnings release: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Earnings release: Q4 2025


Karyopharm Therapeutics Slides: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Slides: Q4 2025


Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year

2026-02-12T12:46:18.000Z - 5 months ago

Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year


Karyopharm Therapeutics Proxy statement: Proxy Filing

Jan 9, 2026, 7:00 AM EST - 7 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 7 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 8, 2025, 7:00 AM EST - 8 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series


Karyopharm Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2025


Karyopharm Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Karyopharm Therapeutics Earnings release: Q3 2025


Karyopharm Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Karyopharm Therapeutics Quarterly report: Q3 2025


Karyopharm Therapeutics Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Karyopharm Therapeutics Slides: Q3 2025


Karyopharm Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2025


Karyopharm Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Quarterly report: Q2 2025


Karyopharm Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Earnings release: Q2 2025


Karyopharm Therapeutics Slides: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Q2 2025


Karyopharm Therapeutics Slides: FY 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: FY 2025


Karyopharm Therapeutics Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Corporate Presentation


Karyopharm Therapeutics Transcript: AGM 2025

May 28, 2025, 9:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: AGM 2025


Karyopharm Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2025


Karyopharm Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Quarterly report: Q1 2025


Karyopharm Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings release: Q1 2025


Karyopharm Therapeutics Slides: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: Q1 2025


Karyopharm Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split


Karyopharm Therapeutics Earnings Call Transcript: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2024


Karyopharm Therapeutics Annual report: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Annual report: Q4 2024


Karyopharm Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q4 2024


Karyopharm Therapeutics Slides: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q4 2024


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 16, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 5, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2024


Karyopharm Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Quarterly report: Q3 2024


Karyopharm Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q3 2024


Karyopharm Therapeutics Slides: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q3 2024


Karyopharm Therapeutics Transcript: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: Study Update


Karyopharm Therapeutics Press release: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Press release: Study Update


Karyopharm Therapeutics Slides: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Study Update


Karyopharm Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2024


Karyopharm Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Quarterly report: Q2 2024


Karyopharm Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Earnings release: Q2 2024


Karyopharm Therapeutics Slides: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Slides: Q2 2024


laaarsas
laaarsas Jul. 27 at 11:53 AM
$KPTI when donkeh come home to roost???
0 · Reply
valueinvestor1998
valueinvestor1998 Jul. 27 at 3:07 AM
2 · Reply
celebratelife
celebratelife Jul. 26 at 7:32 PM
$KPTI Hit piece published with plenty of fishy, inaccurate shit, by doctor with conflict of interest. Think Mike Mano, Richard Paulson, Useless, Weak, in their roles, and careless. They've failed to defend the company in the past against unfounded attacks by hedge shills and others. They don't seem to give a shit as long as they get their fucking millions. We may have to do something since they probably won't, and they're too incompetent and careless to know, when you turn the other cheek to bashers they next take a punch to the belly. No wonder shorts LOVE these guys.
2 · Reply
laaarsas
laaarsas Jul. 26 at 1:33 PM
$KPTI donkeeeeeeh
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 25 at 2:20 PM
$TNXP seth is too washed to be CMO. He should be Executive Chairman of the Board with some fancy emeritus title. Tonix needs a real CEO. I have various ways to turn biopharma companies around. I have done so as an employee, a consultant, and a disgruntled- yet vocal- shareholder. CEOs earn their pay or get the 💩 🗑️ in my book $KPTI CEO Richard “tricky dick” Paulson should have been fired YEARS AGO. $IMRX & $SLS … no complaints there. Both companies have competent leadership. 👍 👍 💎 💎 💎 💎 I don’t keep scraps in my scrapbook - only studs. Seth has Got to Go 🥾 Here is one suggestion:
0 · Reply
laaarsas
laaarsas Jul. 24 at 4:51 AM
$KPTI any donkey in da house?
0 · Reply
celebratelife
celebratelife Jul. 23 at 2:12 PM
$KPTI - RBC Capital Markets, which rates the stock at outperform and a $16 price target (~128% upside based on Monday's close) said the sell-off is unwarranted based on conversations it had with the company. Analyst Brian Abrahams said the cash retention program replaces a guaranteed annual bonus. He added it is unlikely the program is related to an upcoming phase 3 data release of Xpovio (selinexor) in endometrial cancer, adding he gives that trial a 65% possibility of success. As much as I dislike this lousy CEO & Board I could not get myself to sell based on the latest compensation news. It wasn't in itself grounds to sell, although emotionally charged since instead of receiving more money Richard Paulson should get fired.
0 · Reply
elmono
elmono Jul. 22 at 8:59 PM
$KPTI 2 wks to deliver data….
1 · Reply
celebratelife
celebratelife Jul. 22 at 8:37 PM
$KPTI I'm sure many long-term investors remember those days, those painful PRs and calls where this lousy horrible CEO who's never given a damn about shareholders except to spend our money, announced time and again, fucking bad news, fucking delays after fucking delays, and his fucking bonus and big pay was never impacted as shareholder value tanked, nose-dived on his fucking watch. He's not the only one to blame. That wicked Board behind him are also adored by shorts who have made a killing as shareholders have lost their shorts. Shareholders trusted this incompetent wicked CEO / Board clowns in heir public facing role as officers of a publicly traded company. Shorts bet against them. Is there corruptioni? Time will tell. We know who's made money anad who's lost money.
2 · Reply
celebratelife
celebratelife Jul. 22 at 3:36 PM
$KPTI KPTI shorts love Richard Party Paulson and the KPTI Board who've been a dream come true for the scumbags who shorted KPTI for the last 6 years since Paulson was a director and then a CEO. Dream Come True for shorts and HELL for decent people who put their hard-earned dollars into this company trusting this lousy CEO and lousy Board.
1 · Reply
celebratelife
celebratelife Jul. 22 at 3:26 PM
$KPTI CELEBRITY PHOTOS WITH DEMPSEY WOULD NOT HAVE BEEN POSSIBLE IF RICHARD PAULSON / MIKE MASON DISASTER WOULD NOT HAVE GIVEN AWAY MULTIPLE $250K+ DONATIONS OF OUR MONEY (DEMPSEY SPOKESPERSON WHO CONFIRMED THE DONATION LEVEL TO ME PERSONALLY IN A PHONE CALL) WITH NO OVERSIGHT BY THE APPARENTLY USELESS IRRESPONSIBLE LAZY USELESS BOARD MEMBERS WHO APPARENTLY ONLY CARE ABOUT GETTING THEIR FUCKING DIRECT DEPOSITS FOR DOING JACK SHIT.
0 · Reply
laaarsas
laaarsas Jul. 22 at 3:21 PM
$KPTI Stinky management! Slurpy stock! Badness!! No data?? Stock slurp!! How much will financing situation impact possibly positive study results??? Bad risk!
1 · Reply
celebratelife
celebratelife Jul. 22 at 3:20 PM
0 · Reply
celebratelife
celebratelife Jul. 22 at 3:17 PM
$KPTI DREAM TEAM FOR SHORTS : RICHARD “PARTY” PAULSON, BARRY GREENE, MANSOOR MIRZA, GAREN BOHLIN, DEEPA PAKIANATHAN, CHEN SCHOR, MIKE MANO, CHRISTY OLIGER, ZHEN SU, LISA DIPAOLO, MIKE MASON
0 · Reply
elmono
elmono Jul. 22 at 2:44 PM
$GMAB $INCY $KPTI $XBI I am going to make so much money of KPTI that it will dwarf anything so far….8 B potential buy out if EC isxa success and MF OS number continues to hold up…just saying
1 · Reply
JuggernautRaider
JuggernautRaider Jul. 22 at 5:26 AM
$KPTI $XBI karyopharm is screwed. Partially because they kept Tricky Dick Paulson as president for 5 years and keep paying him a fortune as the stock drops to NOTHING. Also, endometrial? Keytruda dominates that market now. Also why did they not pursue a phase 2 for glioblastoma? How did $INCY or $GMAB not buy KPTI for pennies on the dollar and huge tax writeoffs? WHY RICHARD? Why? 😤
2 · Reply
Biotech_Beast
Biotech_Beast Jul. 22 at 1:02 AM
$KPTI Big catalyst upcoming in endometrial cancer (I lean positive on this trial, I think they have a good chance), another readout in multiple myeloma (H2'26) and myelofibrosis (H2'26). $XBI https://seekingalpha.com/article/4923681-karyopharm-therapeutics-stock-balance-sheet-poor-but-catalysts-ahead
0 · Reply
SV777
SV777 Jul. 21 at 4:41 PM
$KPTI previous bonus: contingent on catalysts and positive news New bonus: free money and early They gave themselves free money without conditions
0 · Reply
laaarsas
laaarsas Jul. 21 at 2:16 PM
$KPTI ahahah donkey rebound!!
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 21 at 2:15 PM
$KPTI how the heck does Tricky Dick Richard Paulson still have his job as CEO 😤
1 · Reply
celebratelife
celebratelife Jul. 21 at 1:12 PM
$KPTI Dr. letter to the board 3 years ago - he still stands behind it. We've warned these self-serving incompetent clowns for years but who's to listen. We've been constantly right about how horrible the CEO Paulson and the Board are, but they have the upper hand (power/position), tutes are too passive, and retail is too weak / lazy and has been fooled / duped by some of the management apologists to not call a spade a spade: this Board and CEO suck at running this company, and them getting paid this much while destroying shareholder value is improper. Shorts love them though! https://www.reddit.com/r/KPTI/comments/1387pep/an_open_letter_to_the_board/
0 · Reply
laaarsas
laaarsas Jul. 21 at 11:42 AM
$KPTI I can’t wait any longer goddamn it. I need data now and I need it good!!
1 · Reply